Clinical & Scientific

With new funding, Major Medical Devices is advancing a novel AAA repair device that uses arm access, promising safer procedures and wider patient eligibility.

With new trials in myositis and pediatrics, Cartesian Therapeutics pioneers an outpatient cell therapy, moving beyond cancer to treat chronic autoimmune diseases.

Sanofi deepens its AI partnership with CytoReason in a $16M deal, signaling a major shift in using predictive models to accelerate immunology breakthroughs.

A major pharma giant is betting on artificial intelligence to accelerate cancer drug discovery, a move that could reshape the future of oncology treatment.

The firm is now recruiting for a Phase 1 trial of HWK-007 and has submitted an IND for HWK-016, targeting tough lung, ovarian, and endometrial cancers.

A new partnership aims to bring cutting-edge cancer trials to community clinics, accelerating drug development and expanding patient access to care.

With an expanded Boehringer Ingelheim deal and a new CMO, Enara Bio is set to take its novel 'Dark Antigen' therapy into human trials in 2026.

Replicate Bioscience secures major funding to develop next-gen self-replicating RNA vaccines, aiming for more durable and accessible global health solutions.

A new clinical benchmark published in a Nature journal reveals a Chinese AI is the safest and most effective, challenging Silicon Valley's dominance.

With seasoned executive Adam Rosenberg at the helm, AstronauTx is advancing its novel sleep-focused therapy, backed by major investors, into the Alzheimer's arena.

With enrollment complete for three major trials, MediciNova braces for a transformative year with crucial data expected for its ALS and metabolic disease candidates.

Greenwich LifeSciences execs extend their stock lock-up to 6 years, signaling massive confidence in their breast cancer drug showing an 80% recurrence drop.

In a fierce biotech talent war, Senti Bio's new equity grant for a key hire signals a strategic push for its gene therapy pipeline amid market volatility.

Facing a critical cash shortfall, Cue Biopharma turns to the market, betting its promising cancer and autoimmune pipeline can win over investors.

Molecular Partners readies for a pivotal presentation at the J.P. Morgan conference, showcasing its next-gen DARPin therapeutics for hard-to-treat cancers.

A Utah biotech reports promising results for a novel mRNA therapy that makes cancer cells look like measles, setting the stage for crucial animal trials.

Kodiak Sciences is raising crucial capital with a stock offering, diluting investors but fueling its late-stage retinal drugs. Is this a necessary lifeline or a red flag?

Amid a major corporate overhaul, Emergent BioSolutions secures a key FDA approval, signaling a new era for the firm and for U.S. biodefense strategy.

Health Union's new platform for ATTR amyloidosis isn't just a website. It's a strategic blend of patient support and business innovation. Here's why.

A new alliance between Guardant Health and Trial Library uses AI and massive datasets to dismantle barriers, connecting more patients to vital cancer research.